TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02383277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching of the rib cage muscles

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Rest without stretching (sham)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Constant load exercise on a bike

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Constant load exercise on a bike
Study: NCT01833520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ra-223 Dichloride
Description: Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.
Study: NCT01328925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide Oral Suspension dose based on age:~Age \<12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days
Study: NCT01903187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnligHTN Renal Denervation
Description: Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Renal artery angiogram
Study: NCT02333877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skinlink
Description: suture using Skinlink

Intervention type: OTHER
Group type: OTHER
Intervention: Nylon
Description: conventional suture using nylon
Study: NCT02743520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Lifestar Act III
Description: The Lifestar Act III is a chest-worn continuous Electrocardiogram (ECG) monitor and arrhythmia detector. The device is equipped with four electrodes on a harness with a Bluetooth transceiver and a buzzer. The ECG signals will be transmitted via Bluetooth to an application arranged to process and transmit the ECG recordings.
Study: NCT02834507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: Capsules containing nebicapone 75 mg or 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: Capsules containing nebicapone 75 mg or 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comtan®
Description: Capsules containing entacapone 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet®
Description: levodopa/carbidopa (Sinemet®) dose patient used to take

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet®
Description: levodopa/carbidopa (Sinemet®) dose patient used to take

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet®
Description: levodopa/carbidopa (Sinemet®) dose patient used to take

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sinemet®
Description: levodopa/carbidopa (Sinemet®) dose patient used to take
Study: NCT02035878

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: probiotic intervention: 400mg of probiotic capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study: NCT00546637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Fesoterodine 4mg or 8mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01606930

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Primer Tool
Description: The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs.
Study: NCT01293721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude high - frequency vibration treatment
Description: stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
Study: NCT04199611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: This is a type of fat removal procedure used in plastic surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liposuction
Description: This is a type of fat removal procedure used in plastic surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This is a psycho-social intervention that aims to improve mental health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: This is a psycho-social intervention that aims to improve mental health.
Study: NCT03369405

Intervention type: OTHER
Intervention: NO intervention, patient records review only
Description: There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.

Intervention type: OTHER
Intervention: NO intervention, patient records review only
Description: There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.

Intervention type: OTHER
Intervention: NO intervention, patient records review only
Description: There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
Study: NCT02851758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous mitochondria transplantation
Description: Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
Study: NCT03145285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision.
Study: NCT01402544

Intervention type: DRUG
Group type: OTHER
Intervention: ranibizumab
Description: 0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
Study: NCT02986399

Intervention type: OTHER
Intervention: Fast track patient pathway
Description: Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
Study: NCT01690208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMERALD
Description: Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment \& explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
Study: NCT00653250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: surgery to remove the lung tumor
Study: NCT02459353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03266107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracept
Description: Radiofrequency ablation of the basivertebral nerve using the Intracept System
Study: NCT03674749

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meditation and Hyperbaric Oxygen Treament
Description: Meditation sessions will be combined with hyperbaric oxygen treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation and Hyperbaric Oxygen Treament
Description: Meditation sessions will be combined with hyperbaric oxygen treatment
Study: NCT03731780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Treatment
Description: Targeting individual caries risk factors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine and Remineralization
Description: chlorhexidine mouth wash and remineralizing agent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
Study: NCT00694993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1004723
Description: GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1004723
Description: GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1004723
Description: GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
Study: NCT01327898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: empowerment theory-based small group discussion
Description: four small group discussion sessions followed by one individual counseling session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual resilience counseling
Description: one individual resilience counseling session
Study: NCT02454400

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-surgery physiotherapy
Description: Physiotherapy guided intervention twice a week for nine weeks. The program includes:~1. Active physiotherapy according to a treatment based classification:~   1. Specific exercises and mobilization~  2. Motor control exercises~  3. Traction~2. Tailor-made general supervised exercise program~3. Behavioral approach to reduce fear avoidance and increase activity level.~4. Standardized information about:~   1. the surgery~  2. post-surgery rehabilitation~  3. to stay active

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting-list
Description: Standardized information about:~1. the surgery~2. post-surgery rehabilitation~3. to stay active
Study: NCT03647033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent implantation
Description: The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
Study: NCT00817024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,
Description: 3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules
Description: 3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules
Description: 3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
Study: NCT02716571

Intervention type: OTHER
Group type: OTHER
Intervention: Leukapheresis or Plasmapheresis
Description: Leukapheresis: Donate 5x10\^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE).
Study: NCT00577681

Intervention type: DRUG
Intervention: Antiretroviral Therapy (ART)
Description: Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.

Intervention type: DRUG
Intervention: Antiretroviral Therapy (ART)
Description: Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.

Intervention type: DRUG
Intervention: Antiretroviral Therapy (ART)
Description: Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
Study: NCT02563405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
Study: NCT04245787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self assembling peptide with fluoride
Description: peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self assembling peptide with fluoride
Description: peptide forms a 3D matrix within demineralized carious lesions areas, which enables novo hydroxyapatite crystal formation facilitating the so-called guided enamel regeneration of the lost enamel structure. The peptide has shown encouraging results as a scaffold for enamel regeneration
Study: NCT03249792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2118 (IT)
Description: IT injection
Study: NCT01025791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 0.1 mg
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
Study: NCT03249909

Intervention type: DEVICE
Group type: OTHER
Intervention: Exufiber Ag+
Description: gelling fibre dressing with silver

Intervention type: DEVICE
Group type: OTHER
Intervention: Exufiber Ag+
Description: gelling fibre dressing with silver

Intervention type: DEVICE
Group type: OTHER
Intervention: Exufiber
Description: gelling fibre without silver

Intervention type: DEVICE
Group type: OTHER
Intervention: Exufiber
Description: gelling fibre without silver

Intervention type: DEVICE
Group type: OTHER
Intervention: Exufiber
Description: gelling fibre without silver

Intervention type: DEVICE
Group type: OTHER
Intervention: Aquacel Ag Extra
Description: gelling fibre with silver

Intervention type: DEVICE
Group type: OTHER
Intervention: Aquacel Ag Extra
Description: gelling fibre with silver

Intervention type: DEVICE
Group type: OTHER
Intervention: Aquacel Ag Extra
Description: gelling fibre with silver
Study: NCT00873041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: Supplied as 125 mg, 250 mg and 500 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: Supplied as 125 mg, 250 mg and 500 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Supplied as matching 125 mg, 250 mg and 500 mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Supplied as matching 125 mg, 250 mg and 500 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Supplied as matching 125 mg, 250 mg and 500 mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Supplied as matching 125 mg, 250 mg and 500 mg tablets.
Study: NCT02998411

Intervention type: OTHER
Intervention: Titration
Study: NCT02746887

Intervention type: OTHER
Intervention: Preterm/term cohort

Intervention type: OTHER
Intervention: Preterm/term cohort
Study: NCT04630860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Rotigotine,extended-release microspheres

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Rotigotine,extended-release microspheres

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Rotigotine,extended-release microspheres